New research highlights rising colorectal cancer incidence across multiple age groups in the United States, while a separate clinical trial reports encouraging survival outcomes for patients with advanced kidney cancer receiving targeted therapy.

Colorectal Cancer Incidence Increasing Beyond Younger Adults

The rising incidence of colorectal cancer in young adults has become a growing concern among healthcare professionals. However, a new analysis suggests that the increase is extending beyond younger populations, with overall colorectal cancer rates in the US showing a reversal after more than two decades of decline.

According to an analysis of National Cancer Institute data, colorectal cancer incidence among adults aged 20 to 49 years increased by approximately 3% annually between 2013 and 2022. The American Cancer Society has identified colorectal cancer as the leading cause of cancer-related deaths among adults under 50 in 2026.

Researchers found that colorectal cancer incidence declined from 55.2 cases per 100,000 people in 2000 to 36.7 in 2022, before increasing to 38.3 in 2023.

The sharpest rise was observed among adults aged 45 to 49 years, with incidence increasing by 12.76% annually between 2019 and 2023. Researchers attributed part of this increase to expanded screening recommendations, which lowered the recommended starting age from 50 to 45 years.

However, screening alone does not explain the broader increase across other age groups. Researchers suggested that unidentified risk factors, including potential environmental exposures, may also contribute to the changing trend.

Biological Differences May Explain Aggressive Cancer in Younger Patients

A separate study published in Nature Medicine examined 189 colorectal cancer tumours to investigate why the disease can behave more aggressively in younger patients.

Researchers found that tumours in younger patients contained higher proportions of connective and supporting cells, which have been associated with chemotherapy resistance in several solid cancers.

The analysis also identified increased activity of long non-coding RNAs and stronger cellular signalling patterns that may contribute to cancer cell movement and invasion.

According to study co-author Ana Anderson of Harvard Medical School, the findings provide new research directions for understanding early-onset colorectal cancer.

Targeted Therapy Combination Shows Promise in Advanced Kidney Cancer

In another development, a midstage clinical trial reported encouraging survival outcomes for patients with advanced clear cell renal cell carcinoma.

The study evaluated Votrient, developed by Novartis, and Avastin, developed by Roche, using an alternating treatment schedule in 51 patients.

Both drugs target vascular endothelial growth factor (VEGF), a protein involved in the formation of blood vessels that supply tumours with oxygen and nutrients.

Results published in The Lancet Oncology showed a median overall survival of 63.2 months and median progression-free survival of 24.8 months.

Among 33 patients classified as favorable-risk, median progression-free survival reached 28.5 months, while median overall survival was 76.9 months.

Study leader Dr. Saby George of Roswell Park Comprehensive Cancer Center said the regimen demonstrated outcomes comparable to or potentially better than contemporary immunotherapy combinations in favorable-risk patients, while offering a potential cost advantage.

The findings highlight the continuing role of targeted therapies in advanced kidney cancer treatment, particularly for patients who may not be suitable for immunotherapy. Further research is needed to establish the regimen’s place in current clinical practice.